On Nov. 6, 2019, Bloomage BioTechnology Corporation Limited (stock name: Bloomage Biotech, stock code: 688363) went public officially on the sci-tech innovation board of the Shanghai Stock Exchange (SSE). The company will be raising approximately 2.37 billion CNY through issuing 49.56 million shares in total with the price of 47.79 CNY per share. On the initial day of trading, the company’s market capitalisation reached nearly 40 billion CNY.
Grant Thornton China, as professional service provider of IPO audit, helped the company to overcome the big challenges such as time constraints and large business scale when it comes to the reply and feedback to the enquiry made by the Shanghai Stock Exchange (SSE) and China Securities Regulatory Commission (CSRC). Professional team of Grant Thornton China utilised an array measures such as daily update, weekly update, kick-off meeting, on-site supervision by partners and seamless quality control review in a bid to safeguard the process of IPO.
Ms. ZHAO Yan, Chairman and Executive Director of Bloomage Biotech, said”Grant Thornton China has completed mission impossible in dealing with the IPO process of the company. The team has withstood the formidable challenges and difficulties thanks to their rich experience in providing professional and efficient services for main board market in China.”
The listing ceremony of Bloomage Biotech on the SSE Star Market held in Shanghai, Nov 6, 2019.
Jiang Yonghui, Audit Partner and his team
Group photo of Jiang Yonghui ‘s team, management of Bloomage Biotech and representatives of other professional agencies